FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011230260> ?p ?o ?g. }

• W2011230260 endingPage "642" @default.
• W2011230260 startingPage "630" @default.
• W2011230260 abstract "A new oral fixed-dose combination (FDC) of telmisartan plus ramipril is being introduced in India for the treatment of patients with stage 2 hypertension. The aim of this study was to compare the effectiveness and tolerability of an oral FDC of telmisartan plus ramipril with those of an oral FDC of losartan plus ramipril in adult Indian patients with stage 2 hypertension. This multicenter, prospective, randomized, double-blind, Phase III study was conducted at 5 centers in India. Indian patients aged 18 to 65 years with uncomplicated stage 2 essential hypertension (systolic/diastolic blood pressure [SBP/DBP], >160/>100 mm Hg) were enrolled. After a 2-week placebo run-in period, patients were randomly assigned to receive telmisartan 40 mg plus ramipril 5 mg (T + R) or losartan 50 mg plus ramipril 5 mg (L + R), PO (tablet) QD (before the morning meal) for 8 weeks. Supine blood pressure (BP) was measured at 0 (baseline) and 8 weeks of treatment. The primary end point was the mean reduction from baseline in BP. Responders were classified as patients who had a DBP <90 mm Hg at the end of 8 weeks of therapy. Tolerability was assessed using spontaneous reports of adverse events (AEs) during the follow-up visits and laboratory analyses performed at week 8. A total of 289 patients were enrolled (155 men, 134 women; mean age, 50.74 years). Of these, 8 patients in the T + R group and 7 in the L + R group were lost to follow-up and considered withdrawals. At the end of week 8, the mean percentage reduction in SBP was significantly greater in the T + R group compared with that in the L + R group (24.1% vs 19.4%; P < 0.05). The mean percentage reduction in DBP was also significantly greater in the T + R group compared with that in the L + R group (17.3% vs 12.5%; P < 0.05). The response rates in the T + R and L + R groups were statistically similar (79.1% vs 68.7%). The most common AEs in the T + R and L + R groups were cough (9 [6.1%] and 11 [7.8%] patients, respectively) and headache (7 [4.7%] and 8 [5.7%] patients, respectively). The results in this study in Indian patients with stage 2 essential hypertension suggest that the FDC of T + R controlled BP more effectively compared with the FDC of L + R over 8 weeks. The response rates were similar between the 2 groups. Both treatments were well tolerated." @default.
• W2011230260 created "2016-06-24" @default.
• W2011230260 creator A5009582379 @default.
• W2011230260 creator A5022517247 @default.
• W2011230260 creator A5027291767 @default.
• W2011230260 creator A5027826166 @default.
• W2011230260 creator A5040205781 @default.
• W2011230260 creator A5053342388 @default.
• W2011230260 creator A5056365867 @default.
• W2011230260 creator A5063142939 @default.
• W2011230260 creator A5090766577 @default.
• W2011230260 date "2005-11-01" @default.
• W2011230260 modified "2023-09-27" @default.
• W2011230260 title "Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients" @default.
• W2011230260 cites W1534531622 @default.
• W2011230260 cites W187987924 @default.
• W2011230260 cites W1975603373 @default.
• W2011230260 cites W1999819607 @default.
• W2011230260 cites W2002478856 @default.
• W2011230260 cites W2040158415 @default.
• W2011230260 cites W2056893352 @default.
• W2011230260 cites W2063147499 @default.
• W2011230260 cites W2064099037 @default.
• W2011230260 cites W2067340542 @default.
• W2011230260 cites W2078775644 @default.
• W2011230260 cites W2080742733 @default.
• W2011230260 cites W2085339741 @default.
• W2011230260 cites W2086527516 @default.
• W2011230260 cites W2098780362 @default.
• W2011230260 cites W2106163583 @default.
• W2011230260 cites W2124319319 @default.
• W2011230260 cites W2125256919 @default.
• W2011230260 cites W2127254785 @default.
• W2011230260 cites W2130732372 @default.
• W2011230260 cites W2131033837 @default.
• W2011230260 cites W2135038122 @default.
• W2011230260 cites W2142427285 @default.
• W2011230260 cites W2143954917 @default.
• W2011230260 cites W2153178592 @default.
• W2011230260 cites W2156121263 @default.
• W2011230260 cites W2171333077 @default.
• W2011230260 cites W2284554048 @default.
• W2011230260 cites W2396382238 @default.
• W2011230260 cites W2414167269 @default.
• W2011230260 cites W2465355691 @default.
• W2011230260 cites W2467076505 @default.
• W2011230260 cites W2562329777 @default.
• W2011230260 cites W2726799618 @default.
• W2011230260 cites W3021063182 @default.
• W2011230260 cites W3024026450 @default.
• W2011230260 cites W3145527833 @default.
• W2011230260 cites W3209204398 @default.
• W2011230260 doi "https://doi.org/10.1016/j.curtheres.2005.12.007" @default.
• W2011230260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3966013" @default.
• W2011230260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24678079" @default.
• W2011230260 hasPublicationYear "2005" @default.
• W2011230260 type Work @default.
• W2011230260 sameAs 2011230260 @default.
• W2011230260 citedByCount "2" @default.
• W2011230260 crossrefType "journal-article" @default.
• W2011230260 hasAuthorship W2011230260A5009582379 @default.
• W2011230260 hasAuthorship W2011230260A5022517247 @default.
• W2011230260 hasAuthorship W2011230260A5027291767 @default.
• W2011230260 hasAuthorship W2011230260A5027826166 @default.
• W2011230260 hasAuthorship W2011230260A5040205781 @default.
• W2011230260 hasAuthorship W2011230260A5053342388 @default.
• W2011230260 hasAuthorship W2011230260A5056365867 @default.
• W2011230260 hasAuthorship W2011230260A5063142939 @default.
• W2011230260 hasAuthorship W2011230260A5090766577 @default.
• W2011230260 hasBestOaLocation W20112302601 @default.
• W2011230260 hasConcept C126322002 @default.
• W2011230260 hasConcept C126894567 @default.
• W2011230260 hasConcept C142724271 @default.
• W2011230260 hasConcept C197934379 @default.
• W2011230260 hasConcept C204787440 @default.
• W2011230260 hasConcept C27081682 @default.
• W2011230260 hasConcept C2778375690 @default.
• W2011230260 hasConcept C2779716603 @default.
• W2011230260 hasConcept C2779888176 @default.
• W2011230260 hasConcept C2780288358 @default.
• W2011230260 hasConcept C2908929049 @default.
• W2011230260 hasConcept C71924100 @default.
• W2011230260 hasConcept C84393581 @default.
• W2011230260 hasConceptScore W2011230260C126322002 @default.
• W2011230260 hasConceptScore W2011230260C126894567 @default.
• W2011230260 hasConceptScore W2011230260C142724271 @default.
• W2011230260 hasConceptScore W2011230260C197934379 @default.
• W2011230260 hasConceptScore W2011230260C204787440 @default.
• W2011230260 hasConceptScore W2011230260C27081682 @default.
• W2011230260 hasConceptScore W2011230260C2778375690 @default.
• W2011230260 hasConceptScore W2011230260C2779716603 @default.
• W2011230260 hasConceptScore W2011230260C2779888176 @default.
• W2011230260 hasConceptScore W2011230260C2780288358 @default.
• W2011230260 hasConceptScore W2011230260C2908929049 @default.
• W2011230260 hasConceptScore W2011230260C71924100 @default.
• W2011230260 hasConceptScore W2011230260C84393581 @default.
• W2011230260 hasIssue "6" @default.
• W2011230260 hasLocation W20112302601 @default.

• next